Saifur R Chowdhury, Emily Sirotich, Gordon Guyatt, Daya Gill, Dimpy Modi, Laura M Venier, Syed Mahamad, Mahmudur Rahman Chowdhury, Kerolos Eisa, Carolyn E Beck, Vicky R Breakey, Kerstin de Wit, Stephen Porter, Kathryn E Webert, Adam Cuker, Clare O'Connor, Jennifer MacWhirter -DiRaimo, Justin W Yan, Charles Manski, John G Kelton, Matthew Kang, Gail Strachan, Ziauddin Hassan, Barbara Pruitt, Menaka Pai, Rachael F Grace, Dale Paynter, Jay Charness, Nichola Cooper, Steven Fein, Arnav Agarwal, Hasmik Nazaryan, Ishaq Siddiqui, Russell Leong, Sushmitha Pallapothu, Aaron Wen, Emily Xu, Bonnie Liu, Amirmohammad Shafiee, Preksha Rathod, Henry Kwon, Jared Dookie, Dena Zeraatkar, Lehana Thabane, Rachel Couban, Donald M Arnold
{"title":"Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review.","authors":"Saifur R Chowdhury, Emily Sirotich, Gordon Guyatt, Daya Gill, Dimpy Modi, Laura M Venier, Syed Mahamad, Mahmudur Rahman Chowdhury, Kerolos Eisa, Carolyn E Beck, Vicky R Breakey, Kerstin de Wit, Stephen Porter, Kathryn E Webert, Adam Cuker, Clare O'Connor, Jennifer MacWhirter -DiRaimo, Justin W Yan, Charles Manski, John G Kelton, Matthew Kang, Gail Strachan, Ziauddin Hassan, Barbara Pruitt, Menaka Pai, Rachael F Grace, Dale Paynter, Jay Charness, Nichola Cooper, Steven Fein, Arnav Agarwal, Hasmik Nazaryan, Ishaq Siddiqui, Russell Leong, Sushmitha Pallapothu, Aaron Wen, Emily Xu, Bonnie Liu, Amirmohammad Shafiee, Preksha Rathod, Henry Kwon, Jared Dookie, Dena Zeraatkar, Lehana Thabane, Rachel Couban, Donald M Arnold","doi":"10.1111/ejh.14351","DOIUrl":"https://doi.org/10.1111/ejh.14351","url":null,"abstract":"<p><strong>Objectives: </strong>Evidence-based protocols for managing bleeding emergencies in patients with immune thrombocytopenia (ITP) are lacking. We conducted a systematic review of treatments for critical bleeding in patients with ITP.</p><p><strong>Methods: </strong>We included all study designs and extracted data in aggregate or individually for patients who received one or more interventions and for whom any of the following outcomes were reported: platelet count response, bleeding, disability, or death.</p><p><strong>Results: </strong>We identified 49 eligible studies reporting 112 critical bleed patients with ITP, including 66 children (median age, 10 years), 36 adults (median age, 41.5 years), and 10 patients with unreported age. Patients received corticosteroids (n = 67), IVIG (n = 49), platelet transfusions (n = 41), TPO-RAs (n = 17), and splenectomy (n = 28) either alone or in combination. Studies reported 29 different treatment combinations, the 5 most common were corticosteroids, platelet transfusion and splenectomy (n = 13), corticosteroids and IVIG (n = 13), or splenectomy alone (n = 13); IVIG alone (n = 11); and corticosteroids, IVIG and TPO-RA (n = 8). Mortality among patients with critical bleeds in ITP was 30.6% for adults and 19.7% for children.</p><p><strong>Conclusions: </strong>The effects of individual treatments on patient outcomes were uncertain due to very low-quality evidence. There is a need for a standardized approach to the treatment of ITP critical bleeds.</p><p><strong>Systematic review registration: </strong>CRD42020161206.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T Vogl, Mia Djulbegovic, Sandra Susanibar-Adaniya, Edward Stadtmauer, Oxana Megherea, Adam J Waxman
{"title":"Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis.","authors":"Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T Vogl, Mia Djulbegovic, Sandra Susanibar-Adaniya, Edward Stadtmauer, Oxana Megherea, Adam J Waxman","doi":"10.1111/ejh.14348","DOIUrl":"https://doi.org/10.1111/ejh.14348","url":null,"abstract":"<p><strong>Introduction: </strong>Teclistamab has demonstrated deep responses in patients with multiple myeloma in the MajesTEC-1 study. However, the safety and efficacy of teclistamab in patients with AL amyloidosis are unknown.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with biopsy-proven relapsed/refractory AL amyloidosis who were treated with teclistamab from December 2022 to February 2024 at the University of Pennsylvania. The data cutoff was 2/29/24. Adverse events (AE) were extracted from the electronic medical record. Patients were assessed for hematologic and organ response per consensus guidelines.</p><p><strong>Results: </strong>Eight patients were included in this case series: median age 63 (range 59-67), 75% female, 88% White. All eight patients achieved at least very good partial response (VGPR) and had normalization of free light chains (FLC), and six (75%) patients achieved undetectable FLC levels. Of the six patients with immunofixation completed, all six (100%) achieved hematologic complete response (hCR). The median time to hematologic VGPR and hCR was 13 days (range 12-18 days) and 88 days (range 32-150 days), respectively. The median duration of follow-up was 8.5 months (range 1-14 months). Of the five patients with cardiac involvement, four (80%) achieved a cardiac response. Of the seven patients with renal involvement, two patients already achieved renal response prior to teclistamab, and of the remaining five, three (60%) achieved renal response. Six patients (75%) developed low-grade cytokine release syndrome (CRS). No patients developed ICANS. Neutropenia and AKI both occurred in 25% of patients, respectively.</p><p><strong>Conclusions: </strong>In this series of patients, teclistamab showed outstanding depth of response and was well-tolerated. Teclistamab shows promise in treating patients with relapsed AL amyloidosis.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sara Redondo, María Costa, Maria-Estela Moreno-Martinez, Miguel Arguello-Tomas, Mireia Riba, Olga Aso, Eva Iranzo, Albert Esquirol, Jorge Sierra, Javier Briones, Rodrigo Martino, Edgar Zapico, Irene García-Cadenas
{"title":"Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment.","authors":"Sara Redondo, María Costa, Maria-Estela Moreno-Martinez, Miguel Arguello-Tomas, Mireia Riba, Olga Aso, Eva Iranzo, Albert Esquirol, Jorge Sierra, Javier Briones, Rodrigo Martino, Edgar Zapico, Irene García-Cadenas","doi":"10.1111/ejh.14349","DOIUrl":"https://doi.org/10.1111/ejh.14349","url":null,"abstract":"<p><strong>Objective: </strong>This non-interventional, prospective, single-center study aimed to develop a technique to measure ruxolitinib (RUX) concentrations and provide preliminary data on the distribution of plasma drug levels in patients with steroid refractory (SR) GvHD.</p><p><strong>Methods: </strong>Between April 2023 and May 2024, we analyzed 48 blood samples from 29 patients with SR-GvHD.</p><p><strong>Results: </strong>Median individual plasma concentrations varied across different RUX doses and largely overlapped: 39.2 ng/mL at 10 mg b.i.d (range: 0-73), 13.1 ng/mL at 10-5 mg (range, 6.1-35.6), and 31.6 ng/mL at 5 mg b.i.d (range: 0.7-99.9). Samples taken under non-optimal temperature conditions showed a lower median concentration of 0.77 ng/mL (range: 0-7.4 ng/mL). The four patients who did not respond at days +28 and +180 after RUX initiation (3 with lower gastrointestinal aGvHD, and 1 with ocular, hepatic, and pulmonary cGvHD) showed a median concentration of only (7.4 ng/mL (range, 0-29) ng/mL) with full dosing.</p><p><strong>Conclusions: </strong>The introduction and validation of a liquid chromatography-tandem mass spectrometry method for quantifying plasma RUX concentrations was feasible in our center. Administering predetermined and fixed doses of RUX in patients with SR-GvHD showed highly variable and overlapping plasma drug concentrations. This underscores the potential importance of RUX- pharmacokinetics (PK) monitoring.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kaiya Hassan, Robert Kinan, Ashley Casey, Miranda Dermady, Britta Mizuki, Katerina Stanilova, Heather Savage, Helen Yuan, Emma Hillis, Connor Bertaut, Taylor Guillory, Eric Coons
{"title":"Direct Oral Anticoagulants Versus Warfarin in Patients With Isolated Heparin-Induced Thrombocytopenia or Heparin-Induced Thrombocytopenia With Thrombosis.","authors":"Kaiya Hassan, Robert Kinan, Ashley Casey, Miranda Dermady, Britta Mizuki, Katerina Stanilova, Heather Savage, Helen Yuan, Emma Hillis, Connor Bertaut, Taylor Guillory, Eric Coons","doi":"10.1111/ejh.14350","DOIUrl":"https://doi.org/10.1111/ejh.14350","url":null,"abstract":"<p><p>No existing studies compare oral anticoagulants to treat heparin-induced thrombocytopenia with or without thrombosis (HIT/HITT). This retrospective study evaluated thrombotic and bleeding outcomes in adults treated for HIT/HITT with a direct oral anticoagulant (DOAC) or warfarin between 2012 and 2023 within the Ochsner Health System. Patients with mechanical heart valves, valvular atrial fibrillation, antiphospholipid syndrome, active malignancy, or venous thromboembolism (VTE) within the previous 6 months were excluded. The primary outcome was a composite of new or progressive VTE or arterial thromboembolism. Secondary outcomes included major and clinically relevant non-major bleeding, duration of hospitalization, time to platelet recovery, and incidence of skin necrosis, gangrene, and amputation. Forty-nine patients receiving a DOAC and 30 patients receiving warfarin were included. Baseline characteristics were similar between cohorts. There were non-statistically significant increased rates of both the primary outcome (8.9% vs. 4.3%, p = 0.65) and the composite bleeding outcome (32.7% vs. 23.3%, p = 0.37) in the DOAC cohort. Larger, prospective studies are needed to confirm these findings.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T Richardson, G Kobbe, R Fenk, T Schroeder, M Crysandt, C Neuerburg, Tobias A W Holderried, D Schütte, P Gödel, M Hallek, C Scheid, U Holtick
{"title":"Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis.","authors":"T Richardson, G Kobbe, R Fenk, T Schroeder, M Crysandt, C Neuerburg, Tobias A W Holderried, D Schütte, P Gödel, M Hallek, C Scheid, U Holtick","doi":"10.1111/ejh.14346","DOIUrl":"https://doi.org/10.1111/ejh.14346","url":null,"abstract":"<p><p>A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients relapse. Allogeneic hematopoietic cell transplantation (allo-SCT) is a familiar approach for MM, but responses are often short and side effects burdensome. Simultaneously, allo-SCT provides a unique platform on which novel immune therapies can be employed to improve clinical outcomes. Our work describes the characteristics and outcomes of 128 refractory myeloma patients who underwent allo-SCT at five German centers between 2010 and 2021. The median number of therapies before the transplant was 6. With a median follow-up of 6, 4 years, the median progression-free survival and overall survival were 7 and 19 months, respectively. NRM was 28% after 6 years. OS and PFS were 61% and 45% at 1 year, 49% and 34% at 2 years, and 38% and 25% at 6 years. Achieving a CR before transplant was the single most significant variable before transplant. Allo-SCT yet remains an option for fit patient's refractory to all other treatments available. It is potentially curative for a subset of patients. Finding the characteristics of patients with durable remissions is key to sparing unnecessary toxicity for those unlikely to benefit.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eric J. Niesor, Anne Perez, Serge Rezzi, Andrew Hodgson, Stephane Canarelli, Gregoire Millet, Tadej Debevec, Claire Bordat, Elie Nader, Philippe Connes
{"title":"Featured Cover","authors":"Eric J. Niesor, Anne Perez, Serge Rezzi, Andrew Hodgson, Stephane Canarelli, Gregoire Millet, Tadej Debevec, Claire Bordat, Elie Nader, Philippe Connes","doi":"10.1111/ejh.14344","DOIUrl":"https://doi.org/10.1111/ejh.14344","url":null,"abstract":"<p>The cover image is based on the Article <i>Plasma monomeric ApoA1 and high-density lipoprotein bound ApoA1 are markedly decreased and associated with low levels of lipophilic antioxidants in sickle cell disease: A potential new pathway for therapy</i> by Eric J. Niesor et al., https://doi.org/10.1111/ejh.14288\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"113 6","pages":"i"},"PeriodicalIF":2.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fortunato Morabito, Enrica Antonia Martino, Maria Elena Nizzoli, Annalisa Talami, Stefano Pozzi, Massimo Martino, Antonino Neri, Massimo Gentile
{"title":"Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma","authors":"Fortunato Morabito, Enrica Antonia Martino, Maria Elena Nizzoli, Annalisa Talami, Stefano Pozzi, Massimo Martino, Antonino Neri, Massimo Gentile","doi":"10.1111/ejh.14335","DOIUrl":"10.1111/ejh.14335","url":null,"abstract":"<p>The treatment landscape for relapsed/refractory follicular lymphoma (RR-FL) is marked by a pivotal debate between chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs). While both CAR-T therapy and BsAbs target similar immunobiology and molecular markers, their efficacy comparisons are hindered by the lack of direct clinical trial comparisons. Key trials, such as the ZUMA-5 study, underscore axicabtagene ciloleucel (axi-cel)'s efficacy in treating RR-FL, achieving a 79% complete response rate with a median duration of response exceeding 3 years. Similarly, lisocabtagene maraleucel (liso-cel) in the TRANSCEND FL study reports a 94% complete response rate, emphasizing robust outcomes in heavily pretreated patients. Among BsAbs, mosunetuzumab showed promise in the GO29781 trial, with a 62% overall response rate in heavily pretreated RR-FL patients. Thus, CAR-T therapy offers potential curative benefits with a single infusion. However, its efficacy is tempered by significant adverse events such as cytokine release syndrome (CRS), neurotoxicity, and cytopenias, requiring specialized management and patient monitoring. In contrast, BsAbs provide a more tolerable treatment option counterbalancing by lower response rates and frequent dosing requirements. Personalized treatment strategies are crucial because of these distinct efficacy and safety profiles. When considering cost-effectiveness, both therapies need to be evaluated in the context of their clinical outcomes and quality of life improvements. Cost-effectiveness considerations are essential; while CAR-T therapies incur higher initial costs, their potential for long-term remission may mitigate expenses associated with repeated treatments or hospitalizations. Future research into resistance mechanisms and optimal therapeutic sequencing will further refine RR-FL management strategies.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"114 1","pages":"4-16"},"PeriodicalIF":2.3,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14335","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adi Shacham-Abulafia, Yulia Volcheck, Martin Ellis, Shirley Shapira, Sigal Tavor, Anna Gourevitch, Natalia Kreiniz, Anfisa Stanevski, Pia Raanani, Maya Koren-Michowitz
{"title":"Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.","authors":"Adi Shacham-Abulafia, Yulia Volcheck, Martin Ellis, Shirley Shapira, Sigal Tavor, Anna Gourevitch, Natalia Kreiniz, Anfisa Stanevski, Pia Raanani, Maya Koren-Michowitz","doi":"10.1111/ejh.14330","DOIUrl":"https://doi.org/10.1111/ejh.14330","url":null,"abstract":"<p><strong>Objectives: </strong>Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the ABL1 myristoyl pocket to potentially reduce toxicity and enhance efficacy. It is approved for Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) in patients with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) or those with the T315I mutation.</p><p><strong>Methods: </strong>This retrospective analysis evaluated patients with CML treated with asciminib under a managed-access program across eight Israeli centers from July 2019 to August 2022. We assessed treatment responses, toxicities, event-free survival (EFS), and overall survival (OS) using Kaplan-Meier methods.</p><p><strong>Results: </strong>The study included 30 patients who had received a median of three prior TKIs, with 73% starting asciminib due to intolerance. After a median follow-up of 7.1 months, 85% of those without prior complete cytogenetic response (CCyR) achieved CCyR, and 60% previously not in major molecular response (MMR) attained MMR. Resistance was rare (10%), with no cardiovascular events reported despite high baseline comorbidity (73%). Median EFS was 47 months; median OS was not reached.</p><p><strong>Conclusion: </strong>Asciminib demonstrates significant efficacy and tolerability in heavily pretreated patients with CML-CP, with no new cardiovascular events observed. Further long-term studies are necessary to explore its full cardiovascular impact.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fetal Hemoglobin Decrease During Voxelotor Treatment.","authors":"Gonzalo De Luna, Anoosha Habibi, Stéphane Moutereau, Suella Martino, Jamila Alhamrouni, Celia Morel, Yanis Pelinski, Yosr Zaouali, Frédéric Galactéros, Pablo Bartolucci","doi":"10.1111/ejh.14332","DOIUrl":"https://doi.org/10.1111/ejh.14332","url":null,"abstract":"<p><p>Voxelotor modifies hemoglobin-oxygen affinity improving anemia and reducing hemolysis in sickle cell patients. However, the impact of Voxelotor on fetal hemoglobin (HbF) levels is unknown. We describe here variations of percentage of HbF measured by high performance liquid chromatography and mean corpuscular fetal Hb in a cohort of sickle cell patients treated with Voxelotor at Henri Mondor Sickle Cell Referral Center. Our data show a decrease in HbF levels in sickle cell patients after 6 months of treatment with Voxelotor, which is likely to be associated with an increase in the lifespan of red blood cells that are no longer prematurely removed from the circulation, particularly those with low HbF. This work raises the question of the risk of a rebound effect when stopping Voxelotor, which has a short half-life, during the time it takes to increase HbF.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights","authors":"Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Rosellina Morelli, Teresa Rossi, Antonino Neri, Fortunato Morabito, Massimo Gentile, Ernesto Vigna","doi":"10.1111/ejh.14327","DOIUrl":"10.1111/ejh.14327","url":null,"abstract":"<p>Therapy-related acute promyelocytic leukemia (t-APL) is rare and often linked to previous treatment with alkylating agents or topoisomerase II inhibitors. This report describes three cases of t-APL treated at the Haematology Department of Cosenza Hospital between 2022 and 2024, which occurred after alkylating agents and exemestane, alkylating agents and radiation therapy, alkylating agents, taxane, and checkpoint inhibitor, respectively. Each case was managed with a different therapeutic approach. The first case involved a 71-year-old man with colorectal and breast cancer, who developed low-risk t-APL and achieved complete remission (CR) with ATRA alone. A second 71-year-old man case with colorectal cancer developed high-risk t-APL with PML/RARA and FLT3-ITD fusion transcripts; he achieved CR with idarubicin and ATRA despite severe sepsis and acute heart failure. The third case involved a 74-year-old man with lung squamous cell carcinoma who developed intermediate-risk t-APL following chemoimmunotherapy but unfortunately succumbed to pseudotumor cerebri complications during induction therapy.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"114 1","pages":"195-198"},"PeriodicalIF":2.3,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}